Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-electroporated dendritic cell product
- Development stage
- Phase 2
- Lead developer
- Radboud University Medical Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
The mRNA-electroporated dendritic cell product is an autologous, monocyte-derived dendritic cell (DC)-based cancer immunotherapy developed by Radboud University Medical Center. This therapeutic vaccine is produced by isolating monocytes from a patient, differentiating them into immature dendritic cells, and subsequently electroporating them with mRNA encoding the melanoma-associated antigens gp100 (melanocyte protein PMEL) and tyrosinase. The resulting antigen-loaded DCs are administered intranodally to the patient with the objective of priming and expanding tumor-specific CD4+ and CD8+ T-cell immune responses. It was primarily investigated for the treatment of high-risk uveal melanoma following local therapy, although clinical development was hindered by slow patient accrual in Phase 2 trials.
- Other names
- mRNA-transfected dendritic cell vaccineautologous mRNA-electroporated monocyte-derived dendritic cell vaccination
02
Targets
PMEL (Melanocyte Protein PMEL)TYR (Tyrosinase)
Beyond the preview
Go deeper on mRNA-electroporated dendritic cell product.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-electroporated dendritic cell product.